Table 1.
Changes in the MicroRNA (miRNA) expression in rheumatoid arthritis (RA) patients after abatacept treatment.
| miRNA Name (miRBase ver.17) |
ID | Detection Number (Before) | Detection Number (After) | p Value | Fold |
|---|---|---|---|---|---|
| Before/After | |||||
| Down-regulated miRNAs compered to before treatment | |||||
| hsa-miR-4459 | MIMAT0018981 | 10 | 10 | 0.043 | −1.99 |
| hsa-miR-625* | MIMAT0004808 | 10 | 9 | 0.002 | −1.80 |
| hsa-miR-146a | MIMAT0000449 | 5 | 8 | 0.041 | −1.73 |
| hsa-miR-4505 | MIMAT0019041 | 10 | 10 | 0.021 | −1.72 |
| hsa-miR-4520a-5p, hsa-miR-4520b-5p |
MIMAT0019235, MIMAT0020299 |
4 | 4 | 0.020 | −1.66 |
| hsa-miR-4739 | MIMAT0019868 | 10 | 10 | 0.004 | −1.58 |
| hsa-miR-3616-3p | MIMAT0017996 | 7 | 8 | 0.038 | −1.42 |
| hsa-miR-766 | MIMAT0003888 | 10 | 10 | 0.009 | −1.38 |
| hsa-miR-4442 | MIMAT0018960 | 10 | 10 | 0.043 | −1.28 |
| hsa-miR-149 | MIMAT0000450 | 7 | 5 | 0.026 | −1.28 |
| hsa-miR-4675 | MIMAT0019757 | 9 | 10 | 0.033 | −1.27 |
| hsa-miR-3189-3p | MIMAT0015071 | 5 | 3 | 0.031 | −1.23 |
| hsa-miR-3197 | MIMAT0015082 | 10 | 10 | 0.050 | −1.22 |
| hsa-miR-4716-5p | MIMAT0019826 | 9 | 7 | 0.050 | −1.19 |
| hsa-miR-4508 | MIMAT0019045 | 10 | 10 | 0.039 | −1.16 |
| hsa-miR-409-3p | MIMAT0001639 | 4 | 4 | 0.025 | −1.03 |
| hsa-miR-1288 | MIMAT0005942 | 3 | 8 | 0.031 | −1.03 |
| Up-regulated miRNAs compered to before treatment | |||||
| hsa-miR-3663-5p | MIMAT0018084 | 8 | 6 | 0.038 | 1.05 |
| hsa-miR-3713 | MIMAT0018164 | 5 | 5 | 0.048 | 1.08 |
| hsa-miR-760 | MIMAT0004957 | 10 | 10 | 0.037 | 1.16 |
| hsa-miR-3202 | MIMAT0015089 | 5 | 5 | 0.006 | 1.17 |
| hsa-miR-4317 | MIMAT0016872 | 4 | 5 | 0.038 | 1.20 |
| hsa-miR-657 | MIMAT0003335 | 7 | 6 | 0.043 | 1.20 |
| hsa-miR-4728-3p | MIMAT0019850 | 9 | 9 | 0.014 | 1.24 |
| hsa-miR-4651 | MIMAT0019715 | 10 | 10 | 0.031 | 1.33 |
| hsa-miR-4640-5p | MIMAT0019699 | 10 | 10 | 0.027 | 1.37 |
| hsa-miR-3648 | MIMAT0018068 | 10 | 10 | 0.048 | 1.42 |
| hsa-miR-762 | MIMAT0010313 | 10 | 10 | 0.040 | 1.42 |
| hsa-miR-4669 | MIMAT0019749 | 9 | 9 | 0.037 | 1.43 |
| hsa-miR-1193 | MIMAT0015049 | 9 | 10 | 0.046 | 1.46 |
| hsa-miR-1915 | MIMAT0007892 | 10 | 10 | 0.048 | 1.47 |
| hsa-miR-1225-5p | MIMAT0005572 | 9 | 10 | 0.015 | 1.49 |
| hsa-miR-124 | MIMAT0000422 | 8 | 5 | 0.026 | 1.49 |
| hsa-miR-4299 | MIMAT0016851 | 10 | 10 | 0.004 | 1.58 |
| hsa-miR-3942-3p | MIMAT0019230 | 4 | 3 | 0.037 | 1.62 |
| hsa-miR-3622a-3p | MIMAT0018004 | 7 | 5 | 0.025 | 1.66 |
| hsa-miR-1203 | MIMAT0005866 | 9 | 10 | 0.032 | 1.79 |
| hsa-miR-1231 | MIMAT0005586 | 6 | 7 | 0.047 | 1.80 |
| hsa-miR-4326 | MIMAT0016888 | 6 | 10 | 0.047 | 1.98 |
| hsa-miR-2276 | MIMAT0011775 | 6 | 6 | 0.025 | 2.00 |
| hsa-miR-4664-3p | MIMAT0019738 | 6 | 8 | 0.044 | 2.26 |
| hsa-miR-4259 | MIMAT0016880 | 10 | 9 | 0.012 | 2.43 |
Plasma was collected from RA patients (Table 2) before and three months after treatment with abatacept. Plasma RNA was isolated and then subjected to a miRNA array analysis. miRNAs with significantly altered expression levels, as determined by a paired t-test, are listed. The bold miRNAs are included in Figure 1.